Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections
Key facts
- Who runs it
- Westat
- Where
- Atlanta, Baltimore, Chapel Hill, Chicago, Houston, Los Angeles, Memphis, New Orleans, New York, Philadelphia, San Francisco, Tampa, and Washington D.C., United StatesSee the 13 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 760 people, planned
- Started
- 27 Feb 2026
- Expected to end
- 30 Jun 2029
- Type of study
- Interventional, 3 groups
- Treatments tested
- Doxycycline hyclate delayed released 200 mg
- Doxycycline hyclate delayed released 200 mg weekly
- Per standard of care with quarterly STI testing/treatment and sexual health counseling
- Record updated
- 16 October 2026
Who can take part
- Age
- 13 years to 29 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Age 13-29 years, inclusive
- Self-reports GC, CT, and/or early syphilis diagnosis in the 12 months prior to screening
- Self-reports condomless (oral, vaginal, and/or anal) intercourse at least once in the 30 days prior to screening
- Is at least 45 kilograms (99.2 pounds) in weight
- Fluent in English (able to read, speak, and understand English)
- Willing to undergo all required study procedures; and
- Willing to provide written informed consent to participate in the study
Who cannot take part
- Current or anticipated use of a medication (e.g., barbiturates, phenytoin, lithium, carbamazepine, systemic retinoids, warfarin) with a contraindicated interaction to doxycycline
- Current or planned use of doxycycline for a prolonged period (> 2 weeks) in the 30 days prior to enrollment, including current prescription for doxycycline for STI prophylaxis
- Prolonged antibiotic use (> 2 weeks) within the last 30 days prior to enrollment
- Co-enrollment in any other concurrent interventional research or studies that may interfere with this study, such as an STI prevention trial, unless approved by Protocol Team in writing
- Documented history of tetracycline allergy or self-reports an allergy to tetracyclines
- Any other medical condition, medical/behavioral intervention, or other conditions that, in the opinion of the clinical site Project Lead (PL)/Investigator of Record (IoR) or designee, could interfere with adherence to study procedures or compromise interpretation of study results
- Is male
- Is pregnant, breastfeeding, or planning to become pregnant in the next 12 months
- Does not have consistent access (or anticipated weekly access for 52 weeks of survey completion) to smartphone that can access the HMP app; or
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 13 and 29 years old?
Where in United States
- Ponce de LeonAtlanta, United StatesContact: Christin RootTaking people
- Johns Hopkins UniversityBaltimore, United StatesContact: Jessica ColemanTaking people
- Chapel HillChapel Hill, United StatesContact: Mariam Chicurel-BayardTaking people
- University Illinois ChicagoChicago, United StatesContact: Rachel JacksonTaking people
- Baylor College of MedicineHouston, United StatesContact: Litty KoshyTaking people
- UCLA CareLos Angeles, United StatesContact: Emy ArangoTaking people
- St. Jude Children's Research HospitalMemphis, United StatesContact: Mary DillardTaking people
- Tulane UniversityNew Orleans, United StatesContact: Leslie KozinaTaking people
- Harlem Prevention CenterNew York, United StatesContact: Yan RiveraTaking people
- Penn PreventionPhiladelphia, United StatesContact: Rosemarie KappesNot yet recruiting
- San Francisco Department of Public HealthSan Francisco, United StatesContact: Emily SchaefferTaking people
- University of FloridaTampa, United StatesContact: Elizabeth Enriquez-BruceTaking people
- Children's National Medical CenterWashington D.C., United StatesContact: Justin UnternaherTaking people
About the trial
What the trial wants to find out
The goal of this open-label, randomized trial is to assess the efficacy of doxycycline prophylaxis in reducing incidences of bacterial sexually transmitted infections (STIs) among adolescent and young adult females while also evaluating acceptability and antimicrobial resistance in order to inform public health policy.
The 3 groups in the trial
- On-demand doxyPEPTreatment being tested
Participants will take by mouth doxycycline 200 mg as soon as possible and within 72 hours after any condomless oral, vaginal, and/or anal sex in addition to standard of care STI testing/treatment and sexual health counseling.
Treatment: Doxycycline hyclate delayed released 200 mg
- Weekly doxycyclineTreatment being tested
Participants will take by mouth doxycycline 200 mg weekly regardless of sexual activity in addition to standard of care STI testing/treatment and sexual health counseling.
Treatment: Doxycycline hyclate delayed released 200 mg weekly
- Quarterly STI testing/treatment and sexual health counselingOther group
Participants will be followed per standard of care with quarterly STI testing/treatment and sexual health counseling.
Treatment: Per standard of care with quarterly STI testing/treatment and sexual health counseling
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections Among Adolescent and Young Adult Females in the United States
- Fit questions
- Built from NCT06738407, who can take part
- Record updated
- 16 October 2026